 Home > Medical News > Latest Medical News > New drug for atopic dermatitis!

New drug for atopic dermatitis!

 Last Update: 2022-02-18
 Source: Internet
 Author: User

Tags

acetaminophen 300 mg

isentress 400 mg

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

ASLAN Pharma today announced that the Phase 2b dose-ranging study (TREK-AD) evaluating eblasakimab (ASLAN004) in adult patients with moderate to severe atopic dermatitis (AD) has screened the first patient

TREK-AD is a randomized, double-blind, placebo-controlled, dose-ranging Phase 2b clinical study to evaluate the efficacy and safety of eblasakimab in adult patients with moderate to severe AD who are candidates for systemic therapy

Eblasakimab is a potential first-in-class monoclonal antibody targeting the IL-13 receptor alpha1 subunit (IL-13Rα1), one of the components of the type 2 receptor

Mechanism of action of eblasakimab (ASLAN004)

Recently, ASLAN announced positive data from a proof-of-concept study of eblasakimab

Specifically, in the intention-to-treat (ITT) population, Week 8: The eblasakimab-treated group had a statistically significant improvement in the primary efficacy endpoint (percent change from baseline in the Eczema Area and Severity Index [EASI])61 % compared to 32% in the placebo group

Note: The original text has been deleted

Original source: ASLAN Pharmaceuticals Initiates Phase 2b Study of ASLAN004 (Eblasakimab) in Moderate-to-Severe Atopic Dermatitis

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

A number of Class 1 new drugs were approved for clinical treatment of baldness, atopic dermatitis, etc.

11-05

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

ups united states(221)

united states logo(227)

80 20 company(94)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.

New drug for atopic dermatitis!

Related Articles

A number of Class 1 new drugs were approved for clinical treatment of baldness, atopic dermatitis, etc.